Can-Fite’s CF602 Reverses Erectile Dysfunction in Diabetic Pre-clinical Model: Study Published in Peer-Reviewed Journal Andrologia
June 24 2022 - 7:00AM
Business Wire
- CF602’s unique mechanism of action enables potential
treatment of diabetic patients and may offer an alternative to PDE5
(Viagra, Cialis, Levitra, and Stendra) non-responders accounting
for 30-35% of the $3.6 billion ED market
- Patents granted in numerous healthcare markets including the
U.S., Australia, and Japan
Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CFBI), a
biotechnology company advancing a pipeline of proprietary small
molecule drugs that address inflammatory, cancer and liver
diseases, today announced its study titled “A3 adenosine receptor
allosteric modulator CF602 reverses erectile dysfunction in a
diabetic rat model” was published in the peer-reviewed journal
Andrologia.
A full erectile recovery was achieved following a single dose of
CF602 with restored muscle collagen ratio and endothelial cell
function. Can-Fite’s CF602, an allosteric modulator of the A3
adenosine receptor (A3AR), applied topically or orally in a
diabetic rat model, resulted in increased arterial blood flow and
significant dose-dependent improvements in intracavernosal pressure
(ICM), smooth muscle:collagen ratio, vascular endothelial growth
factor and endothelial nitric oxide synthase.
While oral phosphodiesterase type 5 (PDE5) inhibitors are the
current standard of care for erectile dysfunction (ED), with brands
including Viagra, Cialis, Levitra, and Stendra, an estimated 30% to
35% of ED patients are non-responders, and these drugs can be
contraindicated for people living with diabetes.
Data published in the article suggest CF602 could potentially
offer an alternative treatment to PDE5 inhibitors, particularly to
PDE5 non-responders and diabetics.
"There is a clear and unmet need in the market today for an
effective alternative to PDE5 inhibitors for non-responders to the
leading sexual dysfunction drugs and diabetics, many of whom cannot
safely be prescribed PDE5 inhibitors. With a growing body of data
and IP estate around CF602, we are evaluating potential strategic
partnerships to advance CF602 toward market,” stated Can-Fite CEO
Dr. Pnina Fishman.
According to Zion Market Research, the global ED market was
valued at $3.64 billion in 2021 and is projected to reach $5.94
billion by 2028.
About CF602
CF602 is a novel A3AR allosteric modulator that enhances the
receptor activity in the presence of the native ligand. The
molecule is characterized by high selectivity at the A3AR and is
capable of avoiding receptor desensitization, thus magnifying the
agonist activity at low doses.
About Can-Fite BioPharma Ltd.
Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CFBI) is an
advanced clinical stage drug development Company with a platform
technology that is designed to address multi-billion dollar markets
in the treatment of cancer, liver, and inflammatory disease. The
Company's lead drug candidate, Piclidenoson has completed
enrollment in a Phase III trial for psoriasis. Can-Fite's liver
drug, Namodenoson, is being evaluated in a Phase IIb trial for the
treatment of non-alcoholic steatohepatitis (NASH), and a Phase III
trial for hepatocellular carcinoma (HCC), the most common form of
liver cancer. Namodenoson has been granted Orphan Drug Designation
in the U.S. and Europe and Fast Track Designation as a second line
treatment for HCC by the U.S. Food and Drug Administration.
Namodenoson has also shown proof of concept to potentially treat
other cancers including colon, prostate, and melanoma. CF602, the
Company's third drug candidate, has shown efficacy in the treatment
of erectile dysfunction. These drugs have an excellent safety
profile with experience in over 1,500 patients in clinical studies
to date. For more information please visit: www.can-fite.com.
Forward-Looking Statements
This press release may contain forward-looking statements, about
Can-Fite’s expectations, beliefs or intentions regarding, among
other things, market risks and uncertainties, its product
development efforts, business, financial condition, results of
operations, strategies or prospects. In addition, from time to
time, Can-Fite or its representatives have made or may make
forward-looking statements, orally or in writing. Forward-looking
statements can be identified by the use of forward-looking words
such as “believe,” “expect,” “intend,” “plan,” “may,” “should” or
“anticipate” or their negatives or other variations of these words
or other comparable words or by the fact that these statements do
not relate strictly to historical or current matters. These
forward-looking statements may be included in, but are not limited
to, various filings made by Can-Fite with the U.S. Securities and
Exchange Commission, press releases or oral statements made by or
with the approval of one of Can-Fite’s authorized executive
officers. Forward-looking statements relate to anticipated or
expected events, activities, trends or results as of the date they
are made. Because forward-looking statements relate to matters that
have not yet occurred, these statements are inherently subject to
risks and uncertainties that could cause Can-Fite’s actual results
to differ materially from any future results expressed or implied
by the forward-looking statements. Many factors could cause
Can-Fite’s actual activities or results to differ materially from
the activities and results anticipated in such forward-looking
statements. Factors that could cause our actual results to differ
materially from those expressed or implied in such forward-looking
statements include, but are not limited to: our history of losses
and needs for additional capital to fund our operations and our
inability to obtain additional capital on acceptable terms, or at
all; uncertainties of cash flows and inability to meet working
capital needs; the impact of the COVID-19 pandemic; the initiation,
timing, progress and results of our preclinical studies, clinical
trials and other product candidate development efforts; our ability
to advance our product candidates into clinical trials or to
successfully complete our preclinical studies or clinical trials;
our receipt of regulatory approvals for our product candidates, and
the timing of other regulatory filings and approvals; the clinical
development, commercialization and market acceptance of our product
candidates; our ability to establish and maintain strategic
partnerships and other corporate collaborations; the implementation
of our business model and strategic plans for our business and
product candidates; the scope of protection we are able to
establish and maintain for intellectual property rights covering
our product candidates and our ability to operate our business
without infringing the intellectual property rights of others;
competitive companies, technologies and our industry; statements as
to the impact of the political and security situation in Israel on
our business; and risks and other risk factors detailed in
Can-Fite’s filings with the SEC and in its periodic filings with
the TASE. In addition, Can-Fite operates in an industry sector
where securities values are highly volatile and may be influenced
by economic and other factors beyond its control. Can-Fite does not
undertake any obligation to publicly update these forward-looking
statements, whether as a result of new information, future events
or otherwise.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20220624005117/en/
Can-Fite BioPharma Motti Farbstein info@canfite.com
+972-3-9241114
Can Fite BioPharma (AMEX:CANF)
Historical Stock Chart
From Mar 2024 to Apr 2024
Can Fite BioPharma (AMEX:CANF)
Historical Stock Chart
From Apr 2023 to Apr 2024